The Relationship of the Serum Level of Osteoprotegerin and Bone Mineral Density in Postmenopausal Women

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Anatomical Sciences, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Associate Professor, Department of Radiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Deficiency in bone mineral density is an important factor for osteoporosis in postmenopausal women incurring severe financial burden every year on health care services. Related studies of osteoprotegerin (OPG) are shifting to new parameters in addition to common factors such as aging, menopause, lack of exercise and calcium deficiency etc. In this context, osteoprotegerin serum levels play an important role in the pathogenesis of osteoporosis. The purpose of this study was to investigate the possible relationship between serum level of osteoprotegerin and bone mineral density in postmenopausal women.Methods: 90 patients with a mean age of 61.39 years were enrolled. They were divided in two groups of 45 subjects with and without osteoporosis according to their medical records. Both groups were subjected to densitometry using DAX (Dual-energy X-ray absorptiometry). Bone mineral density (BMD) and T-score were determined. Fresh blood serum samples were taken for analysis of osteoprotegerin serum levels using the enzyme-linked immunosorbent assay (ELISA) method. To rule out heart diseases, they were examined by a cardiologist. Statistical analysis was done using chi-square, t and Mann-Whitney tests.Findings: Bone mineral density of different parts of the body (vertebrae L2, L3, L4, trochanter, femur and hip bones) in normal and osteoporotic postmenopausal women was found to showed significant difference. Comparing the distribution of bone density status (classified as either normal or osteoporotic) showed a significant difference, too (P < 0.001). There was inverse relationship between bone mineral density of lumbar spine (r = -0.4; P = 0.002), hip (r = -0.3; P = 0.030) and femoral neck (R = -0.31; P = 0.020) and serum osteoprotegerin in the two groups.Conclusions: In this study, bone mineral density and osteoprotegerin showed an inverse relationship. 

Keywords

References

  1. Herrera A, Martinez AA, Ferrandez L, Gil E, Moreno A. Epidemiology of osteoporotic hip fractures in Spain. Int Orthop 2006; 30(1): 11-4.
  2. Kesavan C, Mohan S. Bone mass gained in response to external loading is preserved for several weeks following cessation of loading in 10 week C57BL/6J mice. J Musculoskelet Neuronal Interact 2010; 10(4): 274-80.
  3. Richmond B. DXA scanning to diagnose osteoporosis: do you know what the results mean? Cleve Clin J Med 2003; 70(4): 353-60.
  4. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12(1): 17-25.
  5. Bayat N, Haji Amini Z, Alishiri Gh, Ebadi A, Hosseini M, Laluee A. Frequency of osteoporosis and osteopenia in post-menopausal military family's wome. J Army Univ Med Sci I R Iran 2008; 6(1): 25-30. [In Persian].
  6. Woolf AD, Akesson K. Preventing fractures in elderly people. BMJ 2003; 327(7406): 89-95.
  7. Christenson ES, Jiang X, Kagan R, Schnatz P. Osteoporosis management in post-menopausal women. Minerva Ginecol 2012; 64(3): 181-94.
  8. Stojanovic OI, Lazovic M, Lazovic M, Vuceljic M. Association between atherosclerosis and osteoporosis, the role of vitamin D. Arch Med Sci 2011; 7(2): 179-88.
  9. Shohani M, Rasouli F, Haji Amiri P, Mahmoudi M, Hasanpoor A. Evaluation of osteoporosis preventive factors in menopausal women referred to the health care centers of Ilam University of Medical Sciences in 2004. J Shahrekord Univ Med Sci 2010; 11(4): 49-56. [In Persian].
  10. Zhang F, He C, Chen G, Li F, Gao H. Association analyses of osteoprotegerin gene polymorphisms with bone mineral density in Chinese postmenopausal women. Med Oncol 2013; 30(1): 389.
  11. Witasp A, Carrero JJ, Hammarqvist F, Qureshi AR, Heimburger O, Schalling M, et al. Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. Eur J Clin Invest 2011; 41(5): 498-506.
  12. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 2010; 68(5): 959-63.
  13. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004; 15(6): 457-75.
  14. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88(3): 1024-8.
  15. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97(3 Suppl): 887-92.
  16. Frost ML, Grella R, Millasseau SC, Jiang BY, Hampson G, Fogelman I, et al. Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. Calcif Tissue Int 2008; 83(2): 112-20.
  17. Celczynska BL, Horst SW, Bychowiec B, Wykretowicz A, Wesoly J, Michalak M. The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. Kardiol Pol 2011; 69(6): 573-8.
  18. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14(4): 518-27.
  19. Avalos I, Rho YH, Chung CP, Stein CM. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26(5 Suppl 51): S5-13.
  20. Brandstrom H, Stiger F, Lind L, Kahan T, Melhus H, Kindmark A. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun 2002; 293(1): 13-7.
  21. Ueland T, Bollerslev J, Wilson SG, Dick IM, Islam FM, Mullin BH, et al. No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. Bone 2007; 40(1): 175-81.
  22. Bakhireva LN, Laughlin GA, Bettencourt R, Barrett-Connor E. Does osteoprotegerin or receptor activator of nuclear factor-kappaB ligand mediate the association between bone and coronary artery calcification? J Clin Endocrinol Metab 2008; 93(5): 2009-12.
  23. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22(4): 549-53.
  24. Hofbauer LC, Cepok S, Hemmer B. Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropathol 2004; 107(6): 575-7, author.
  25. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106(10): 1192-4.
  26. Arko B, Prezelj J, Kocijancic A, Komel R, Marc J. Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. Maturitas 2005; 51(3): 270-9.
  27. Pennisi P, Russo E, Gaudio A, Veca R, D'Amico F, Mangiafico RA, et al. The association between carotid or femoral atherosclerosis and low bone mass in postmenopausal women referred for osteoporosis screening. Does osteoprotegerin play a role? Maturitas 2010; 67(4): 358-62.
  28. Hoseinnezhad R, Saghafi H, Rahmani M, Baradaran Nobari B, Larijani B. The relationship between serum levels of LDL and ligand-receptor activator of nuclear factor kB in women before and after menopause. Iran J Diabetes Lipid Disord 2009; 8(2): 159-66. [In Persian].
Journal of Isfahan Medical School
Volume 32, Issue 318 - Serial Number 318
November and December 2015
Pages 2349-2359

Files

History

  • Receive Date: 07 May 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics